GlaxoSmithKline (GSK) is set to trial an investigational rheumatoid arthritis drug otilimab for the treatment of pneumonia caused by Covid-19 infection.
GSK identified the drug after screening its portfolio and pipeline for potential against Covid-19. The company acquired the rights to otilimab from German biotech firm MorphoSys in 2013, noted Reuters.
According to a company spokesman, otilimab could potentially ease the effect of the coronavirus on the lungs but not suppress it directly.
The drug’s trial will enrol approximately 800 Covid-19 patients, as per website ClinicalTrials.gov. Initial data are expected to be available by the end of this year.
FierceBiotech quoted GSK as saying: “We believe that otilimab may be able to help to block the effects of one of the types of cytokine (known as GM-CSF). We plan to start a phase 2 clinical trial by the end of May.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAccording to the news agency, the supply of the drug is ‘currently being used for the Covid-19 and rheumatoid arthritis trials’ but GSK will work to maximise the supply if the drug yields positive results in Covid-19 trials.
A spokesperson was quoted as saying: “We will work with regulators and manufacturing partners to determine how to provide access of otilimab to patients with Covid-19 who urgently need treatments.”
GSK initially joined Covid-19 efforts with the Coalition for Epidemic Preparedness Innovations (CEPI) alliance, under which the company agreed to provide access to its pandemic vaccine adjuvant platform to help support Covid-19 vaccine candidates.
The company also agreed to invest $250m in Vir Biotechnology for the research and development (R&D) of antibodies to treat Covid-19 infection.
Furthermore, GSK signed a letter of intent for a partnership with Sanofi to develop an adjuvanted vaccine for Covid-19.
Roche is another company studying a rheumatoid arthritis drug to treat Covid-19 pneumonia. Roche unit Genentech received US Food and Drug Administration (FDA) approval to conduct a Phase III trial of its rheumatoid arthritis drug Actemra (tocilizumab) for adults with severe Covid-19 pneumonia.
